Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Xoma ( (XOMA) ).
XOMA Royalty Corporation, a company involved in royalty management, completed its acquisition of HilleVax, Inc. on September 17, 2025. The acquisition was executed through a merger agreement, where XOMA’s subsidiary merged with HilleVax, making it a wholly owned subsidiary of XOMA. The transaction involved a tender offer for HilleVax’s shares, which included a cash payment and a contingent value right. This strategic move positions XOMA to potentially enhance its market presence and operational capabilities.
The most recent analyst rating on (XOMA) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Xoma stock, see the XOMA Stock Forecast page.
Spark’s Take on XOMA Stock
According to Spark, TipRanks’ AI Analyst, XOMA is a Neutral.
Xoma’s overall stock score reflects a blend of positive technical momentum and strategic corporate developments, offset by financial challenges and valuation concerns. The merger with Turnstone Biologics is a significant positive factor, while the negative P/E ratio and profitability issues weigh on the score.
To see Spark’s full report on XOMA stock, click here.
More about Xoma
Average Trading Volume: 56,468
Technical Sentiment Signal: Buy
Current Market Cap: $449.2M
Learn more about XOMA stock on TipRanks’ Stock Analysis page.